The Changing Microbiologic Epidemiology of Community-Acquired Pneumonia
- 1 November 2013
- journal article
- research article
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 125 (6) , 31-42
Abstract
Community-acquired pneumonia (CAP) is a common infectious disease in the United States and the incidence continues to grow as the aging population increases. Overall, in-hospital patient mortality rates have been reported to be as high as 18%. Management of patients with CAP has been challenged by the evolution of resistant pathogens (particularly Streptococcus pneumoniae and Staphylococcus aureus) that have reduced susceptibility to recommended standard antimicrobial agents. Streptococcus pneumoniae continues to be the most frequently identified pathogen in CAP and recently, S. aureus has been found to be the second most often identified pathogen. Data from the SENTRY Antimicrobial Surveillance Program has shown declining susceptibility of pneumococci to penicillin, amoxicillin/clavulanate, and ceftriaxone from 1998 through 2011. In the Assessing Worldwide Resistance Evaluation (AWARE) surveillance program, > 50% of all S. aureus isolates from patient bloodstream infections, skin and skin structure infections, and pneumonia were methicillin-resistant. Stratifying risk factors to identify patients at risk for community-acquired multidrug-resistant pathogens should be considered when selecting therapy. Differences in microbiology and outcomes have been noted in patients presenting from the community with recent exposure to the health care system (eg, nursing home residents, patients with a recent hospital admission). These patients are at an increased risk of an infection caused by a multidrug-resistant pathogen. Understanding a patient's risk for drug-resistant pathogens will allow the physician to choose an appropriate empiric treatment regimen to optimize clinical outcomes.Keywords
This publication has 91 references indexed in Scilit:
- Community-Acquired Pneumonia Episode Costs by Age and Risk in Commercially Insured US Adults Aged ≥50 YearsApplied Health Economics and Health Policy, 2013
- Pneumococcal Carriage and Invasive Disease in Children Before Introduction of the 13-valent Conjugate VaccineThe Pediatric Infectious Disease Journal, 2013
- Diagnoses and Timing of 30-Day Readmissions After Hospitalization for Heart Failure, Acute Myocardial Infarction, or PneumoniaJAMA, 2013
- Costs of Healthcare- and Community-Associated Infections With Antimicrobial-Resistant Versus Antimicrobial-Susceptible OrganismsClinical Infectious Diseases, 2012
- Summary of Ceftaroline Activity against Pathogens in the United States, 2010: Report from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) Surveillance ProgramAntimicrobial Agents and Chemotherapy, 2012
- LEADER Program Results for 2009: an Activity and Spectrum Analysis of Linezolid Using 6,414 Clinical Isolates from 56 Medical Centers in the United StatesAntimicrobial Agents and Chemotherapy, 2011
- Increase in Prevalence of Streptococcus pneumoniae Serotype 6C at Eight Children's Hospitals in the United States from 1993 to 2009Journal of Clinical Microbiology, 2011
- Activity of Ceftaroline against Recent Emerging Serotypes of Streptococcus pneumoniae in the United StatesAntimicrobial Agents and Chemotherapy, 2010
- Occurrence, Distribution, and Origins of Streptococcus pneumoniae Serotype 6C, a Recently Recognized SerotypeJournal of Clinical Microbiology, 2009
- Health Care-Associated Pneumonia and Community-Acquired Pneumonia: a Single-Center ExperienceAntimicrobial Agents and Chemotherapy, 2007